GWPH - GW Pharma's Epidyolex OK'd in Australia

GW Pharmaceuticals (GWPH) announces that the Australian Therapeutic Goods Administration ((TGA)) has approved EPIDYOLEX (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome ((LGS)) or Dravet syndrome ((DS)) in patients two years of age and older.LGS/DS are rare, treatment-resistant, severe forms of epilepsy. GW has partnered with Chiesi Australia to make this medicine available in Australia, and the Company will now work with Australia’s Pharmaceutical Benefits Advisory Committee to secure reimbursement for the medicine.The bull case for GW Pharmaceuticals is that they have a clear path of growing current revenues in the short term, a promising pipeline, and reasonable cash reserves, writes Nick Cox in his article "GW Pharmaceuticals: A Buy After Stock Price Decline". In Q2, total revenues jumped 68.5% Y/Y to $121.3M with 64.6% increase in Epidiolex sales to $117.7M vs. Q2 2019.Wall Street Analysts Rating is Bullish with price target of $190.69, whereas Quant Rating is Neutral.See pharmaceutical development

For further details see:

GW Pharma's Epidyolex OK'd in Australia